Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS

Description du projet

Analyse des données sur les hémopathies malignes pour améliorer l’accès aux nouvelles thérapies

Les hémopathies malignes (HM) sont un groupe hétérogène de maladies aux diagnostics compliqués et aux traitements extrêmement complexes. L’objectif du projet HARMONY PLUS, financé par l’UE, consiste à collecter, stocker et analyser les informations actuelles sur les HM afin d’accélérer et de soutenir le processus décisionnel pour permettre aux patients d’accéder à de nouvelles thérapies. Le projet utilise les capacités de la plateforme de mégadonnées HARMONY pour répondre aux besoins non satisfaits en élargissant sa portée pour intégrer les néoplasmes myéloprolifératifs, notamment la leucémie myéloïde chronique, la polycythémie vraie, la thrombocythémie essentielle et la myélofibrose ainsi que les troubles lymphoprolifératifs, y compris le lymphome de Hodgkin, la macroglobulinémie de Waldenström et toutes les HM absentes du précédent projet HARMONY.

Objectif

Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are extremely complex, and advances in patient diagnosis and therapies slow due to the low number of patients per centre. Thus, there is a need to harmonise, store, and analyse the current HM information to speed-up and support the decision-making process for patients’ access to new therapies.

HARMONY PLUS takes advantage of the capabilities of the HARMONY Big Data platform to match these unmet needs by expanding its scope to incorporate myeloproliferative neoplasms, including chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; and lymphoproliferative disorders, including Hodgkin’s lymphoma, Waldenström macroglobulinemia and all the other rare HMs not covered by HARMONY Project. In parallel, HARMONY PLUS will continue to refine and define the Core Outcome Sets (COS), especially for these new HMs to ensure the use by researchers of useful common outcomes relevant to all stakeholders. As previously accomplished in HARMONY, HARMONY PLUS is committed to pursue the maximum ethical and legal requirements, particularly to ensure patient’s right to privacy.

Data-driven research within Europe will be enhanced by converting the current HARMONY platform into an Integrated Services Platform to serve as a valuable tool to support clinical trial design and use of available data as a control arm. This platform, combined with a HaemoDatabank repository with information about HMs patient biological samples across Europe, will facilitate a more efficient research and clinical trial design, and consequently will promote collaborations with recognised databases outside Europe. From the regulatory point of view, HARMONY PLUS will be a valuable technology tool during the evaluation of new treatments and drugs by also considering the patients’ needs.

Coordinateur

FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
Contribution nette de l'UE
€ 1 606 368,02
Adresse
PARQUE SANTA CLARA
42002 Soria
Espagne

Voir sur la carte

Région
Centro (ES) Castilla y León Soria
Type d’activité
Research Organisations
Liens
Coût total
€ 2 474 594,27

Participants (42)